• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Former FDA Commissioners Call for Expanded Use of Real-World Evidence

Former FDA Commissioners Call for Expanded Use of Real-World Evidence

August 26, 2019

Three former FDA commissioners unveiled a report last week that proposes a dozen ways to expand the use of real-world evidence (RWE) and real-world data (RWD).

The commissioners, on behalf of the Bipartisan Policy Center, urged the FDA to issue guidance on how sponsors can use RWE for new indications for existing drugs and support postapproval requirements.

“Real world data and evidence are also necessary for the implementation of many novel development and approval pathways,” says the report, which was endorsed by Robert Califf, Mark McClellan and Andrew von Eschenbach. As medicine becomes more personalized, they said, “randomized controlled trials will become increasingly less feasible.”

According to a survey of sponsors conducted by the Tufts Center for the Study of Drug Development, use of RWD/RWE by drug sponsors already is widespread. Of the 30 companies responding to the survey, 97 percent said they use RWD in a variety of ways, including in support of drug applications.

Respondents reported having very little direct experience with regulatory agencies accepting RWE for labeling (17 percent) or labeling changes (13 percent), but more experience using RWE for postapproval safety assessments (55 percent) and in postmarketing studies (57 percent).

Twenty percent of companies said they spend more than $5 million on RWE analytics, 60 percent said they spend more than $5 million on research studies and data, and 86 percent plan to increase their RWD budgets by 11 percent to 25 percent in coming years.

The commissioners’ report also points to increased support for adaptive approval pathways, in which data and evidence generated on a smaller, distinctively defined patient population, allows regulatory approval for those specific subpopulations.

The former commissioners also endorsed leveraging technology to gain input directly from patients to help conduct clinical trials and expanding the use of AI to support trial development.

Read the full report here: https://bit.ly/30parRL.

Data Sources Used in Support of an NDA by Sponsor

  Current Planned In three years Have not used
Demographic Data 8 0 1 6
Claims Data 7 1 3 6
Patient Reported
Outcome/Surveys
7 3 1 4
Biomarkers and/or Genomics 6 3 1 4
Prescription Data 6 0 1 7
EHR Clinical Data 5 2 4 4
Electronic Medical Images 4 0 3 6
Protocol Feasibility (regarding
commitment requirements)
4 2 1 6
Personal Health
Devices/Wearables
1 3 5 5
Social Media Data 1 0 2 11

Source: Tufts CSDD

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing